Other approaches to suppress GIP action (yet to undergo clinical trials) include various GIP receptor antagonist peptides, a small molecule GIP receptor antagonist (SKL-14959) and an anti-GIP monoclonal antibody (HCR-188) [51, 56]
Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy
Reaney M, Mathieu C, stenson CG, Matthaei S, Krarup T, Kiljaski J, et al
Common GLP-1 side effects include nausea, constipation, and appetite reductioneffects that typically diminish within 2-4 weeks as your body adjusts
The realistic timeline Based on the current state of the clinical program, regulatory precedent, and publicly available information from Eli Lilly, here is the most realistic projection: Mid to late 2026: Remaining TRIUMPH, TRANSCEND, and SYNERGY Phase 3 results are reported